![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-pricing-of-1-1-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules-302148673.html
https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-1-for-8-reverse-stock-split-302144966.html
https://www.prnewswire.com/news-releases/seelos-therapeutics-provides-update-on-top-line-results-from-its-amyotrophic-lateral-sclerosis-als-study-with-sls-005-iv-trehalose-302092918.html
https://www.fiercebiotech.com/biotech/seelos-sugar-molecule-fails-improve-als-disease-severity-midstage-trial
https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-receipt-of-minutes-from-its-end-of-phase-ii-meeting-with-the-united-states-food-and-drug-administration-fda-highlighting-modifications-to-the-primary-and-secondary-endpoints-of-its-phase-ii-study-of-302039967.html
https://www.prnewswire.com/news-releases/seelos-therapeutics-inc-releases-letter-to-its-stockholders-302021395.html
https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-closing-of-public-offering-302003489.html
https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-pricing-of-5-55-million-public-offering-302000013.html
https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-proposed-public-offering-301999640.html
https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-the-selection-of-sls-002-intranasal-racemic-ketamine-for-inclusion-in-the-us-department-of-defenses-adaptive-platform-trial-to-evaluate-potential-treatments-for-post-traumatic-stress-disorder-pt-301997327.html